Featured Publications
NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
Marks A, Antaya R, Balsamo L, Cardinale K, Cheron R, Frumberg D, Gentile V, Habib L, Puthenpura V, Zhang H. NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies. Neuro-Oncology 2022, 24: i129-i129. PMCID: PMC9165028, DOI: 10.1093/neuonc/noac079.469.Peer-Reviewed Original ResearchTuberous sclerosisPediatric patients 2 yearsYale-New Haven Children's HospitalInoperable plexiform neurofibromasPatients 2 yearsOwn side effectsYears of ageNeurofibromatosis type 1Multidisciplinary clinicNeurocutaneous syndromeChildren's HospitalPlexiform neurofibromaNeuro-oncologySide effectsSubspecialty consultationClinicType 1Young adultsSclerosisSyndromeHospitalTherapyAgeTreatmentClinical reasoning
2012
A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy
Marks AM, Packer RJ. A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy. Seminars In Pediatric Neurology 2012, 19: 43-48. PMID: 22641075, DOI: 10.1016/j.spen.2012.02.015.Peer-Reviewed Original ResearchConceptsCentral nervous system tumorsSecondary central nervous system tumorsNervous system tumorsPediatric malignanciesSystem tumorsPrimary brain tumorsRole of treatmentCancer predisposition syndromeTreatment of leukemiaSecondary malignanciesSecondary tumorsBrain tumorsPredisposition syndromeMalignancyTumorsTreatmentRemarkable stridesSyndromeEtiologyLeukemiaIncidenceDiagnosis